-
Product Insights
New![]()
Net Present Value Model: Pfizer Inc’s GBT-021601
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GBT-021601 in Sickle Cell Disease
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. GBT-021601 in Sickle Cell Disease Drug Details: GBT-021601 is under development for the treatment...
-
Product Insights
New![]()
Net Present Value Model: Nuvalent Inc’s NUV-655
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – LR-19024 in Osteoarthritis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.LR-19024 in Osteoarthritis Drug Details:LR-19024 is under development for the treatment of osteoarthritis. It is administered by...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Olvimulogene nanivacirepvec in Fallopian Tube Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Olvimulogene nanivacirepvec in Fallopian Tube Cancer Drug Details: Olvimulogene nanivacirepvec (GL-ONC1) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Nogapendekin Alfa in Gastroesophageal (GE) Junction Carcinomas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Nogapendekin Alfa in Gastroesophageal (GE) Junction Carcinomas Drug Details: nogapendekin alfa (ALT-803) is under development...
-
Company Profile
![]()
Global Bio-chem Technology Group Co Ltd – Company Profile
Global Bio-chem Technology Group Co Ltd (GBT) is a manufacturer of corn refined and corn based biochemical products. The company offers corn starch, corn sweeteners, corn gluten, corn fiber, corn oil, and corn gluten feed. GBT also offers amino acids, modified starches, and polyol chemicals. Its products find applications in cosmetics, pharmaceuticals, food and beverages, chemical, and textiles industries. It markets corn refined and lysine products in Norway, Germany, Brazil, Holland, Korea, the US, and Japan. The company operates production...
Add to Basket -
Product Insights
![]()
GBT Realty Corp – Eden House Condominium Tower – Tennessee
Equip yourself with the essential tools needed to make informed and profitable decisions with our GBT Realty Corp - Eden House Condominium Tower - Tennessee report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep...
-
Product Insights
![]()
GBT Realty Corp – One22One Broadway Office Tower – Tennessee
Equip yourself with the essential tools needed to make informed and profitable decisions with our GBT Realty Corp - One22One Broadway Office Tower - Tennessee report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep...
-
Company Profile
![]()
Global Blood Therapeutics Inc – Company Profile
Global Blood Therapeutics Inc (GBT), a subsidiary of Pfizer Inc, is a clinical-stage biopharmaceutical company. The company discovers and develops oxbryta (voxelotor), inclacumab and GBT601. Its products are used for the treatment of various therapeutic areas which includes sickle cell disease (SCD), chronic vaso-occlusive crisis (VOC) prevention, acute VOC re-admission prevention and hemolytic anemia. GBT offers products in tablet form for both children and adults under the brand name Oxbryta. The company also focuses on the development of therapies that...
Add to Basket
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.